RECRUITING

Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this research is to determine whether a 16-week virtually supervised aerobic and resistance exercise program is feasible in patients receiving first-line chemotherapy after surgery for ovarian or endometrial cancer and if it will improve lower extremity function (function of the legs), lessen chemotherapy-induced peripheral neuropathy (CIPN; numbness or tingling in the hands or feet), and if there is any effect on inflammatory blood markers (the level of a certain marker in the blood that is associated with inflammation; redness and swelling).

Official Title

Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy

Quick Facts

Study Start:2022-04-02
Study Completion:2025-04-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04997096

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:FEMALE
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Newly diagnosed patients with stages III-IV ovarian or endometrial cancer
  2. * Receiving first-line carboplatin and paclitaxel chemotherapy after surgery
  3. * ≥18 years, children under the age of 18 will be excluded due to rarity of disease
  4. * Physician's clearance to participate in moderate-vigorous intensity exercise
  5. * Able to read, write, and understand English
  6. * Ability to understand and the willingness to sign an informed consent document
  7. * Willing to undergo two venous blood draws for the study
  1. * Pre-existing musculoskeletal, neurological, or cardiorespiratory conditions, as determined by the treating oncologist
  2. * Participants with uncontrolled intercurrent illness, as determined by the treating oncologist
  3. * Participants with psychiatric illness/social situations that would limit compliance with study requirements, as determined by the treating oncologist
  4. * Participants who have received prior chemotherapy for cancer treatment (e.g. taxanes for breast cancer)

Contacts and Locations

Study Contact

Christina Dieli-Conwright, PhD
CONTACT
(617) 582-8321
ChristinaM_Dieli-Conwright@dfci.harvard.edu

Principal Investigator

Christina Dieli-Conwright, PhD
PRINCIPAL_INVESTIGATOR
Dana-Farber Cancer Institute

Study Locations (Sites)

Dana Farber Cancer Institute
Boston, Massachusetts, 02215
United States

Collaborators and Investigators

Sponsor: Dana-Farber Cancer Institute

  • Christina Dieli-Conwright, PhD, PRINCIPAL_INVESTIGATOR, Dana-Farber Cancer Institute

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-04-02
Study Completion Date2025-04-30

Study Record Updates

Study Start Date2022-04-02
Study Completion Date2025-04-30

Terms related to this study

Keywords Provided by Researchers

  • Ovarian Cancer
  • Ovarian Carcinoma
  • Ovarian Cancer Stage IV
  • Ovarian Cancer Stage III
  • Ovarian Cancer Stage 3
  • Endometrial Cancer
  • Aerobic Exercise
  • Strength Training
  • Cardiovascular training

Additional Relevant MeSH Terms

  • Ovarian Cancer
  • Ovarian Carcinoma
  • Ovarian Cancer Stage IV
  • Ovarian Cancer Stage III
  • Ovarian Cancer Stage 3
  • Endometrial Cancer
  • Endometrial Cancer Stage